TY - JOUR
T1 - Methylglyoxal levels in human colorectal precancer and cancer
T2 - Analysis of tumor and peritumor tissue
AU - Chou, Chu Kuang
AU - Yang, Po Chun
AU - Tsai, Pei Yun
AU - Yang, Hsin Yi
AU - Tsai, Kun Feng
AU - Chen, Tsung Hsien
AU - Liao, Kai Sheng
AU - Chen, Chi Yi
AU - Lee, Jen Ai
N1 - Funding Information:
Funding: This research was funded by the Department of Research of Ditmanson Medical Foundation Chia-Yi Christian Hospital (grant number R105-20), and the Ministry of Science and Technology, Taiwan (grant number MOST 109-2320-B-038-037-).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/12
Y1 - 2021/12
N2 - Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is increasing; therefore, an understanding of its oncogenic mechanisms is critical for improving its treatment and management. Methylglyoxal (MGO) has a highly reactive aldehyde group and has been suggested to play a role in oncogenesis. However, no standardized data are currently available on MGO levels in colorectal precancerous and cancerous lesions. We collected 40 matched colorectal tumor and peritumor tissues from patients with low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive cancer (IC). MGO levels increased between LGD, HGD, and IC tumor tissues (215.25 ± 39.69, 267.45 ± 100.61, and 587.36 ± 123.19 µg/g protein, respectively; p = 0.014). The MGO levels in peritumor tissue increased and were significantly higher than MGO levels in tumor tissue (197.99 ± 49.40, 738.09 ± 247.87, 933.41 ± 164.83 µg/g protein, respectively; p = 0.002). Tumor tissue MGO levels did not correlate with age, sex, underlying disease, or smoking status. These results suggest that MGO levels fluctuate in progression of CRC and warrants further research into its underlying mechanisms and function in tumor biology.
AB - Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is increasing; therefore, an understanding of its oncogenic mechanisms is critical for improving its treatment and management. Methylglyoxal (MGO) has a highly reactive aldehyde group and has been suggested to play a role in oncogenesis. However, no standardized data are currently available on MGO levels in colorectal precancerous and cancerous lesions. We collected 40 matched colorectal tumor and peritumor tissues from patients with low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive cancer (IC). MGO levels increased between LGD, HGD, and IC tumor tissues (215.25 ± 39.69, 267.45 ± 100.61, and 587.36 ± 123.19 µg/g protein, respectively; p = 0.014). The MGO levels in peritumor tissue increased and were significantly higher than MGO levels in tumor tissue (197.99 ± 49.40, 738.09 ± 247.87, 933.41 ± 164.83 µg/g protein, respectively; p = 0.002). Tumor tissue MGO levels did not correlate with age, sex, underlying disease, or smoking status. These results suggest that MGO levels fluctuate in progression of CRC and warrants further research into its underlying mechanisms and function in tumor biology.
KW - Human colorectal cancer
KW - Methylglyoxal
KW - Precancerous and cancerous
KW - Tumor and peritumor tissue
UR - http://www.scopus.com/inward/record.url?scp=85121611195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121611195&partnerID=8YFLogxK
U2 - 10.3390/life11121319
DO - 10.3390/life11121319
M3 - Article
AN - SCOPUS:85121611195
SN - 0024-3019
VL - 11
JO - Life
JF - Life
IS - 12
M1 - 1319
ER -
